Crystal Arthropathies: Clinical Trials

52 trials for Crystal Arthropathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

41 completed, 4 terminated, 3 recruiting, 2 unknown. 52 Phase 3, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 352Completed 41, Terminated 4, Recruiting 3, Unknown 2, Active not recruiting 1, Withdrawn 1
Phase 25Completed 2, Recruiting 1, Terminated 1, Unknown 1

Follow Crystal Arthropathies: new trials by email Literature Review of Crystal Arthropathies trials Research Report on Crystal Arthropathies

Trials (filtered) newest first · largest first

All 52 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tigulixostat (IBI128) vs Febuxostat in Gout
Febuxostat, Tigulixostat - Gout
Phase 3Active not recruitingInnovent Biologics Technology Limited (Shanghai R&D Center)6002026-03-172026-09-01
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Allopurinol, Dotinurad - Gout
Phase 3RecruitingCrystalys Therapeutics5002025-08-012026-11-12
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
AR882 50 mg, AR882 75 mg, Placebo - Gout, Arthritis, Gouty
Phase 3CompletedArthrosi Therapeutics8662025-03-112026-09-28
Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis
Etoricoxib + Betamethasone fixed dose, Etoricoxib fixed dose - Gout Arthritis, Gout Attack
Phase 3RecruitingLaboratorios Silanes S.A. de C.V.722025-01-272025-04-03
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
AR882 50 mg, AR882 75 mg, Placebo - Gout, Arthritis, Gouty
Phase 3CompletedArthrosi Therapeutics8182024-06-262026-10-14
Extension Study of ABP-671 in Participants With Gout
ABP-671, Allopurinol - Gout
Phase 2 / Phase 3TerminatedAtom Therapeutics Co., Ltd432024-04-222025-07-16
Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia
Febuxostat 20MG Tablets, Febuxostat 20MG Placebo, AR882 25MG - Primary Gout, Hyperuricemia
Phase 2 / Phase 3UnknownGuangzhou Ruianbo Pharmaceutical Technology Co., Ltd6362024-04-222024-09-19
A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis
Qingzhu Granules, Qingzhu Granules Placebo - Gouty Arthritis
Phase 3CompletedTasly Pharmaceutical Group Co., Ltd4722023-11-072026-02-27
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
ABP-671, Allopurinol, Placebo - Gout
Phase 2 / Phase 3CompletedAtom Therapeutics Co., Ltd3002023-08-112025-12-22
Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed Administration
Adenuric - Gout
Phase 3CompletedUniversity Hospital, Rouen92023-08-022026-11-06
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
Tigulixostat, Allopurinol, Placebo - Gout, Hyperuricemia
Phase 3CompletedLG Chem22022023-03-302025-07-22
A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients
Epaminurad 6 mg, Epaminurad 9 mg, Febuxostat 40 mg - Gout
Phase 3CompletedJW Pharmaceutical6122023-03-212026-05-04
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
Dapansutrile, Placebo Tablet - Acute Gout Flare, Gout Attack
Phase 2 / Phase 3RecruitingOlatec Therapeutics, Inc.3002023-01-062026-03-11
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
Tigulixostat, Placebo - Gout, Hyperuricemia
Phase 3CompletedLG Chem3542022-10-252025-10-29
A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout
Dotinurad, Febuxostat, Dotinurad Matched Placebo - Gout
Phase 3CompletedEisai Co., Ltd.4512021-12-212025-07-30
A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
SHR4640, Allopurinol - Gout
Phase 3CompletedJiangsu HengRui Medicine Co., Ltd.7792021-06-152025-01-24
Impact of Colchicine in Hospitalized Colombian Patients With COVID-19
Colchicine 0.5 MG, CONTROL GROUP - Corona Virus Infection
Phase 3TerminatedFundación Universitaria de Ciencias de la Salud1282021-04-302022-02-23
A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout
SHR4640 dose1, SHR4640 dose2, Placebo oral tablet - Gout
Phase 3CompletedJiangsu HengRui Medicine Co., Ltd.5942019-07-162022-06-13
Efficacy of Intra-articular NSAID Versus Corticosteroid in the Treatment of Shoulder and Knee Conditions: A Randomized, Double-Blind, Prospective Study
Shoulder injection, knee injection - Knee Arthritis, Shoulder Arthritis
Phase 3UnknownOSF Healthcare System502018-08-012018-08-06
Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis
Colchicine opocalcium 1mg, Prednisone : Cortancyl 20mg - Chondrocalcinosis
Phase 3CompletedLille Catholic University1112018-02-052026-04-17

Showing 20 of 52. Sign in to see all of them.

Narrower conditions

Gout (46)  ·  Arthritis, Gouty (10)  ·  Hyperuricemia (9)  ·  Arthritis (7)  ·  Rheumatic Diseases (6)  ·  Genetic Diseases, Inborn (4)  ·  Joint Diseases (4)  ·  Metabolic Diseases (4)  ·  Metabolism, Inborn Errors (4)  ·  Musculoskeletal Diseases (4)  ·  Purine-Pyrimidine Metabolism, Inborn Errors (4)  ·  Renal Insufficiency, Chronic (2)  ·  Arthralgia (1)  ·  Chondrocalcinosis (1)  ·  Coronavirus Infections (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (50)  ·  Nutritional and Metabolic Diseases (50)  ·  Joint Diseases (48)  ·  Musculoskeletal Diseases (48)  ·  Genetic Diseases, Inborn (46)  ·  Metabolic Diseases (46)  ·  Metabolism, Inborn Errors (46)  ·  Purine-Pyrimidine Metabolism, Inborn Errors (46)  ·  Arthritis (45)  ·  Rheumatic Diseases (44)  ·  Pathologic Processes (11)  ·  Pathological Conditions, Signs and Symptoms (11)  ·  Connective Tissue Diseases (6)  ·  Skin and Connective Tissue Diseases (6)

Interventions

Allopurinol (15)  ·  Febuxostat (13)  ·  canakinumab (6)  ·  lesinurad (6)  ·  Triamcinolone Acetonide (5)  ·  rilonacept (5)  ·  Colchicine (3)  ·  Pegloticase (3)  ·  Indomethacin (2)  ·  dotinurad (2)  ·  Betamethasone (1)  ·  Celecoxib (1)  ·  Control Groups (1)  ·  Etoricoxib (1)  ·  Interleukin 1 Receptor Antagonist Protein (1)

Sponsors

Novartis Pharmaceuticals (7)  ·  Ardea Biosciences, Inc. (6)  ·  Takeda (6)  ·  Regeneron Pharmaceuticals (5)  ·  Savient Pharmaceuticals (3)  ·  Arthrosi Therapeutics (2)  ·  Atom Therapeutics Co., Ltd (2)  ·  Jiangsu HengRui Medicine Co., Ltd. (2)  ·  LG Chem (2)  ·  Astellas Pharma Taiwan, Inc. (1)  ·  Crystalys Therapeutics (1)  ·  Eisai Co., Ltd. (1)  ·  Fundación Universitaria de Ciencias de la Salud (1)  ·  Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd (1)  ·  Innovent Biologics Technology Limited (Shanghai R&D Center) (1)

Countries

United States (29)  ·  Canada (13)  ·  Australia (11)  ·  Germany (11)  ·  China (8)  ·  Taiwan (8)  ·  New Zealand (7)  ·  Poland (7)  ·  Belgium (6)  ·  South Africa (6)  ·  Spain (6)  ·  Lithuania (5)  ·  Colombia (4)  ·  France (4)  ·  Georgia (4)

Top investigators

Chris Storgard, MD (4)  ·  Robert Evans, PharmD (3)  ·  Hyungjin Cho, MD (2)  ·  Nihar Bhakta, MD (2)  ·  Robert Keenan, MD (2)  ·  Bin Liu, M.D. (1)  ·  Chunde Bao (1)  ·  Eric Houvenagel, Pr (1)  ·  Gowrie Balasubramaniam, MB ChB (1)  ·  Haiwang Ji, M.D. (1)  ·  Hong Liu, M.D. (1)

Results publications

PMID 21353107, PMID 22052584, PMID 35835008, PMID 18600509, PMID 24122883, PMID 24286509, PMID 24588936, PMID 31203212, PMID 39929260, PMID 16339094, PMID 16439323, PMID 18975369, PMID 19286847, PMID 20131255, PMID 20370912, PMID 21846852, PMID 21849262, PMID 22132950, PMID 22316106, PMID 22436129, PMID 22549879, PMID 23375025, PMID 23485476, PMID 23683134, PMID 24447425, PMID 25028379, PMID 26013187, PMID 27564409, PMID 27821644, PMID 28877949, PMID 29029210, PMID 30073793, PMID 31079535, PMID 31986264, PMID 32020029, PMID 32346093, PMID 38251496, PMID 40897521, PMID 42582081, PMID 42816092

NIH funding

2008 (1), 2009 (1), 2015 (1)